Disposition of Flavonoids via Glucuronidation, Critical Role of Efflux Transporte

通过葡萄糖醛酸化处理黄酮类化合物,外排转运的关键作用

基本信息

  • 批准号:
    9267482
  • 负责人:
  • 金额:
    $ 52.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-06-05 至 2020-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dietary flavonoids exert a broad range of biological effects including anticancer, antioxidant, antiosteoperosis, cholesterol lowering, and anti-aging, which make them attractive for preventing cancer and cardiovascular ailments and for impeding the progress of degenerative diseases. However, these compounds are poorly bioavailable, which impedes their development as viable drugs. The long-term goal of our study is to determine how efflux transporters of hydrophilic phase II conjugates control the overall disposition of flavonoids and determine their biological fate in vivo. The central hypothesis for the present research proposal is that the local and systemic bioavailability of a flavonoid will be improved by modulating the function of a critical efflux transporter responsible for its distributin to the local target organs (e.g., colon) or the systemic circulation. Our central hypothesis is a step beyond the classical hypothesis that bioavailabilities of drugs can only be improved if more are absorbed and/or less of the absorbed amount is metabolized. The Specific Aims of this renewal proposal are to: (1) construct precise quantitative cellular metabolic models to describe the kinetics of glucuronide formation and efflux at the molecular level; (2) determine the quantitative structure-efflux relationships (QSERs) for three key efflux transporters of flavonoid glucuronides: BCRP, MRP2, and MRP3; and (3) establish a glucuronidation classification system to map which flavonoid is likely to have good bioavailability by manipulating a particular efflux transporter. Successful completion of our research project will significantly advance the basic sciences as well as practical knowledge that may be used to improve the bioavailability of flavonoids and relevant drugs for human health.
说明(申请人提供):膳食中的黄酮类化合物具有广泛的生物学作用,包括抗癌、抗氧化、抗骨质疏松症、降低胆固醇和抗衰老,使其在预防癌症和心血管疾病以及阻止退行性疾病的进展方面具有吸引力。然而,这些化合物的生物利用度很低,这阻碍了它们作为可行药物的开发。我们研究的长期目标是确定亲水性II相结合物的外排转运体如何控制类黄酮类化合物的整体处置,并决定它们在体内的生物命运。目前研究建议的中心假设是,黄酮类化合物的局部和全身生物利用度将是 通过调节负责将其分配到局部靶器官(例如,结肠)或体循环的关键外流转运体的功能而得到改善。我们的中心假说超越了经典假说,即只有当更多的药物被吸收和/或更少的吸收量被代谢时,药物的生物利用度才能提高。这项更新建议的具体目标是:(1)构建精确的定量细胞代谢模型,在分子水平上描述葡萄糖醛酸苷的形成和外排动力学;(2)确定黄酮类葡萄糖醛酸苷的三个关键外排转运体:BCRP、MRP2和MRP3的定量结构-外流关系(QSERs);以及(3)建立葡萄糖醛酸化分类系统,通过操纵特定的外排转运体来绘制哪种黄酮类化合物可能具有良好的生物利用度。我们的研究项目的成功完成将极大地促进基础科学和实用知识的发展,这些知识可用于提高类黄酮和相关药物对人类健康的生物利用度。

项目成果

期刊论文数量(81)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Glucuronidation: driving factors and their impact on glucuronide disposition.
  • DOI:
    10.1080/03602532.2017.1293682
  • 发表时间:
    2017-05
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
    Yang G;Ge S;Singh R;Basu S;Shatzer K;Zen M;Liu J;Tu Y;Zhang C;Wei J;Shi J;Zhu L;Liu Z;Wang Y;Gao S;Hu M
  • 通讯作者:
    Hu M
Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.
  • DOI:
    10.1021/mp200300w
  • 发表时间:
    2011-12-05
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    Wu B;Zhang S;Hu M
  • 通讯作者:
    Hu M
A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2).
  • DOI:
    10.1007/s11095-012-0817-2
  • 发表时间:
    2012-11
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Wu, Baojian;Jiang, Wen;Yin, Taijun;Gao, Song;Hu, Ming
  • 通讯作者:
    Hu, Ming
Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.
Regioselective glucuronidation of flavonols by six human UGT1A isoforms.
  • DOI:
    10.1007/s11095-011-0418-5
  • 发表时间:
    2011-08
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Wu, Baojian;Xu, Beibei;Hu, Ming
  • 通讯作者:
    Hu, Ming
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MING HU其他文献

MING HU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MING HU', 18)}}的其他基金

Elucidating High Oral Fluid Exposure Mechanisms of Buprenorphine to Reduce Dental Caries
阐明丁丙诺啡的高口腔液暴露机制以减少龋齿
  • 批准号:
    10765181
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
Development of Drug Detoxifying Bacteria for Chemotherapy Induced Gut Injury
开发用于化疗引起的肠道损伤的药物解毒细菌
  • 批准号:
    10560782
  • 财政年份:
    2021
  • 资助金额:
    $ 52.66万
  • 项目类别:
Development of Drug Detoxifying Bacteria for Chemotherapy Induced Gut Injury
开发用于化疗引起的肠道损伤的药物解毒细菌
  • 批准号:
    10252721
  • 财政年份:
    2021
  • 资助金额:
    $ 52.66万
  • 项目类别:
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities
中药方剂小柴胡汤抗伊立替康肠道毒性的机制和药代动力学研究
  • 批准号:
    10262912
  • 财政年份:
    2020
  • 资助金额:
    $ 52.66万
  • 项目类别:
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities
中药方剂小柴胡汤抗伊立替康肠道毒性的机制和药代动力学研究
  • 批准号:
    10686830
  • 财政年份:
    2020
  • 资助金额:
    $ 52.66万
  • 项目类别:
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities
中药方剂小柴胡汤抗伊立替康肠道毒性的机制和药代动力学研究
  • 批准号:
    10463682
  • 财政年份:
    2020
  • 资助金额:
    $ 52.66万
  • 项目类别:
Inhibition of Oral Tumorigenesis by Antitumor B
抗肿瘤 B 抑制口腔肿瘤发生
  • 批准号:
    10516360
  • 财政年份:
    2016
  • 资助金额:
    $ 52.66万
  • 项目类别:
Inhibition of Oral Tumorigenesis by Antitumor B
抗肿瘤 B 抑制口腔肿瘤发生
  • 批准号:
    10170283
  • 财政年份:
    2016
  • 资助金额:
    $ 52.66万
  • 项目类别:
Disposition of Flavonoids via Glucuronidation, Critical Role of Efflux Transporte
通过葡萄糖醛酸化处理黄酮类化合物,外排转运的关键作用
  • 批准号:
    8870372
  • 财政年份:
    2006
  • 资助金额:
    $ 52.66万
  • 项目类别:
Disposition of Flavonoids via Metabolic Interplay
通过代谢相互作用处理黄酮类化合物
  • 批准号:
    7784367
  • 财政年份:
    2006
  • 资助金额:
    $ 52.66万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 52.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了